BMC Immunology is a prominent open-access journal published by BMC that has been at the forefront of immunological research since its inception in 2000. Based in the United Kingdom, this journal aims to advance the understanding of immune system functions and disorders through high-quality, peer-reviewed articles. With an impressive scope encompassing various facets of immunology, BMC Immunology has earned a Q3 ranking in the Immunology category according to the 2023 category quartiles, demonstrating its growing impact and relevance in the scientific community. Researchers and professionals will find valuable insights in its array of published works, spanning both foundational studies and innovative applications. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and advancement in the field. For those looking to stay updated on the latest developments in immunology, BMC Immunology stands as an essential resource for researchers, professionals, and students alike.

IMMUNOBIOLOGY is a prestigious academic journal published by Elsevier GmbH that significantly contributes to the fields of hematology and immunology. With its ISSN 0171-2985 and E-ISSN 1878-3279, this journal has been disseminating impactful research since 1979, positioning itself at the forefront of immunological and hematological advances. The journal holds a commendable ranking of Q2 in Hematology and Q3 in both Immunology and Immunology and Allergy, indicating its relevance and influence within the scientific community, as reflected by its Scopus rankings. Although IMMUNOBIOLOGY operates under a subscription model, it remains dedicated to expanding knowledge across disciplines, fostering innovative research, and facilitating connections among researchers, professionals, and students. Situated in Munich, Germany, this journal is continually evolving and aims to remain an essential resource for the latest discoveries and insights in the realms of immunity and blood disorders, ultimately enhancing our understanding of complex biological systems.

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

Welcome to the European Journal of Immunology, a premier peer-reviewed journal dedicated to advancing the field of immunology and allergy research. Established in 1971 and published by Wiley, this esteemed journal has been consistently ranked in the top quartile (Q1) across its categories, highlighting its significant impact within the scientific community. With an impressive Scopus ranking, the journal occupies the 64th position in Immunology and Allergy and the 74th in the broader sector of Immunology and Microbiology, demonstrating its vital role in driving innovation and knowledge in immunological studies. The European Journal of Immunology publishes high-quality original research, comprehensive reviews, and insightful commentary, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to understanding the complexities of the immune system. Although not an open-access journal, it offers various subscription options to ensure that institutions and individuals can access pivotal research that shapes the future of immunology.

JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

INTERNATIONAL IMMUNOLOGY, published by OXFORD UNIV PRESS, stands out as a premier journal in the field of immunology, providing a vital platform for disseminating groundbreaking research and innovative developments within the discipline. With an impressive Q1 ranking in Immunology and Allergy, as well as in Medicine (miscellaneous), it consistently showcases high-impact studies that contribute to the advancement of immunological knowledge. The journal spans over three decades, from its inception in 1989 to its ongoing contributions as of 2024, thus solidifying its reputation in the scientific community. Researchers, professionals, and students will find valuable articles that delve into the complexities of immune responses, therapeutic interventions, and emerging immunological paradigms, ensuring INTERNATIONAL IMMUNOLOGY remains at the forefront of knowledge in the life sciences.

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

Immunotherapy Advances, published by Oxford University Press, stands at the forefront of the rapidly evolving field of immunology and microbe interactions, focusing specifically on novel immunotherapeutic strategies and their clinical applications. Established in 2021, this peer-reviewed journal aims to disseminate high-quality research that contributes to the understanding and advancement of immunotherapeutic techniques, potentially transforming patient care in immunology. With a current Scopus rank of #140 out of 236 in the realm of Immunology, placing it in the 40th percentile, Immunotherapy Advances is positioned to be an integral resource for researchers, healthcare professionals, and students eager to stay updated with groundbreaking findings and methodologies. The journal is dedicated to fostering innovative discussions and collaborations, ensuring open access to vital research that influences treatment paradigms globally.